Yan Leyfman: Advancing CAR-T Therapy for Solid Tumors
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Advancing CAR-T Therapy for Solid Tumors.
CAR-γδ T cells are emerging as a game-changer in immunotherapy! Unlike classic CAR-αβ T cells, which face challenges with solid tumor penetration and MHC limitations, CAR-γδ T cells recognize antigens independently—making them a powerful option for allogeneic therapy.
In this study, researchers developed CAR-γδ T cells targeting Claudin18.2, showing superior cytotoxicity against solid tumors compared to traditional CAR-αβ T cells. These findings pave the way for a more universal and effective CAR-T strategy in CLDN18.2-positive cancers.
Key Takeaways:
- MHC-independent antigen recognition
- Enhanced tumor-killing efficiency
- Potential for broader allogeneic use.”
Authors: Yueqi Zhao, Yinghui Li, Shuaiqi Wang, Jingyi Han, Mingyang Lu, Yupeng Xu, Wenhua Qiao, Menghua Cai, Yi Xu, Yu Hu, Jianmin Zhang, Hui Chen, Wei He.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023